Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 1.00 |
| ▸ | LCK | P06239 | 8/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967661 | 1.00 | TNK2 (1.00) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2974800 | 1.00 | TNK2 (1.00) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2975018 | 0.95 | TNK2 (0.90) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2976170 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2975441 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2977407 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL17859385 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2975713 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2977801 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK | |
| SCHEMBL2975922 | 0.94 | TNK2 (0.89) | TNK2LCKABL1LYNBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-12637432-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-12281117-B2 | Small molecule immune agonists and immune targeting compounds and application thereof | SHENZHEN UNIVERSITY (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-119070018-A | Antenna module and related performance improvement method thereof | 联发科技股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| WO-2013103899-A2 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2013-07-11 | — | — | WO | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281117-B2 | Small molecule immune agonists and immune targeting compounds and application thereof | IFNG, IFNAR1, STING1 | TNK2 1107/4885LCK 334/4885ABL1 2017/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | TNK2 1075/4885LCK 18/4885ABL1 2730/4885 |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | TNK2 3/4885LCK 133/4885ABL1 188/4885 |
| US-12637432-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TTK | TNK2 4/4885LCK 126/4885ABL1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.